{"doi":"10.1111/liv.15322","title":"Contribution of a genetic risk score to ethnic differences in fatty liver disease","abstract":"Abstract Background and aims Susceptibility to fatty liver disease (FLD) varies among individuals and between racial/ethnic groups. Several genetic variants influence FLD risk, but whether these variants explain racial/ethnic differences in FLD prevalence is unclear. We examined the contribution of genetic risk factors to racial/ethnic‐specific differences in FLD. Methods A case–control study comparing FLD patients ( n = 1194) and population‐based controls ( n = 3120) was performed. Patient characteristics, FLD risk variants ( PNPLA3‐ rs738409 + rs6006460, TM6SF2‐ rs58542926, HSD17B13‐ rs80182459 + rs72613567, MBOAT7 / TMC4‐ rs641738, and GCKR‐ rs1260326) and a multi‐locus genetic risk score (GRS) were examined. The odds of FLD for individuals with different risk factor burdens were determined. Results Hispanics and Whites were over‐represented (56% vs. 38% and 36% vs. 29% respectively) and Blacks under‐represented (5% vs. 23%) among FLD patients, compared to the population from which controls were selected ( p < .001). Among cases and controls, Blacks had a lower and Hispanics a greater, net number of risk alleles than Whites ( p < .001). GRS was associated with increased odds of FLD (OR Q5vsQ1 = 8.72 [95% CI = 5.97–13.0], p = 9.8 × 10 −28 ), with the association being stronger in Hispanics (OR Q5vsQ1 = 14.8 [8.3–27.1]) than Blacks (OR Q5vsQ1 = 3.7 [1.5–11.5], P‐interaction = 0.002). After accounting for GRS, the odds of FLD between Hispanics and Whites did not differ significantly (OR = 1.06 [0.87–1.28], p = .58), whereas Blacks retained much lower odds of FLD (OR = 0.21, [0.15–0.30], p < .001). Conclusions Blacks had a lower and Hispanics a greater FLD risk allele burden than Whites. These differences contributed to, but did not fully explain, racial/ethnic differences in FLD prevalence. Identification of additional factors protecting Blacks from FLD may provide new targets for prevention and treatment of FLD.","journal":"Liver International","year":2022,"id":240474,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":45,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8902,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":73350,"name":"Jonathan C. Cohen","orcid":"0000-0003-0984-2864","position":1,"is_corresponding":false},{"id":73352,"name":"Helen H. Hobbs","orcid":"0000-0002-8700-9897","position":2,"is_corresponding":false},{"id":263005,"name":"Julia Kozlitina","orcid":"0000-0001-7720-2290","position":3,"is_corresponding":false},{"id":868407,"name":"Maddie Kubiliun","orcid":null,"position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-19T00:22:46.554789Z","pmid":"35620859","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}